A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 In Subjects With Idiopathic Parkinson's Disease

Trial Profile

A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 In Subjects With Idiopathic Parkinson's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs PF 6649751 (Primary) ; Trimethobenzamide
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 11 May 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.
    • 06 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top